PharmGKB: The Pharmacogenomics Knowledge Base

Drug/Small Molecule:
trazodone

2D structure

Overview

Generic Names: Trazodona [INN-Spanish]; Trazodone Hcl; Trazodone Hydrochloride; Trazodonum [INN-Latin]; trazodone
Trade Names: Beneficat; Bimaran; Desirel; Desyrel; Molipaxin; Pragmazone; Sideril; Thombran; Tombran; Trazalon; Trazodil; Trazodon; Trazolan; Trazonil; Trialodine; Trittico
PharmGKB Accession Id: PA451744

Description

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) (source: Drug Bank)

Indication

For the treatment of depression. (source: Drug Bank)

ATC Therapeutic Category

  • N06AX:Other antidepressants

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS. (source: Drug Bank)

Pharmacology

Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma. (source: Drug Bank)

Food Interactions

Avoid St.John's Wort.
Avoid alcohol.
Take with food. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic (source: Drug Bank)

Protein Binding

89-95% (source: Drug Bank)

Absorption

Well absorbed following oral administration. (source: Drug Bank)

Toxicity

LD<sub>50</sub>=96mg/kg (i.v. in mice) (source: Drug Bank)

Isomeric SMILES Code:

c1ccn2c(c1)nn(c2=O)CCCN3CCN(CC3)c4cccc(c4)Cl (source: Drug Bank)

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2D6
  •   
  •   
  • PK
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
CYP3A
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP3A4
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP3A5
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
HTR2A
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
HTR2C
  •   
  • PD
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
KCNH2
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
SLC6A4
  •   
  • PD
  •   
  •   
  •   
Publications

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
HTR1A Uncurated Annotation (source: Drug Bank)
HTR2A Uncurated Annotation (source: Drug Bank)
ADRA1A Uncurated Annotation (source: Drug Bank)
ADRA1B Uncurated Annotation (source: Drug Bank)
ADRA2A Uncurated Annotation (source: Drug Bank)
HRH1 Uncurated Annotation (source: Drug Bank)
SLC6A2 Uncurated Annotation (source: Drug Bank)
SLC6A4 Uncurated Annotation (source: Drug Bank)

The following drugs are in curated knowledge about this drug.

  Drug Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
clarithromycin
  •   
  •   
  • PK
  •   
  •   
Publications

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

Drug Description
acenocoumarol Uncurated Annotation Trazodone decreases the anticoagulant effect (source: Drug Bank)
almotriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
aminoglutethimide Uncurated Annotation The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed. (source: Drug Bank)
amiodarone Uncurated Annotation The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed. (source: Drug Bank)
amitriptyline Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Amitriptyline by decreasing Amitriptyline metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Amitriptyline efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
amoxapine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Amoxapine by decreasing Amoxapine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Amoxapine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
amprenavir Uncurated Annotation The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed. (source: Drug Bank)
anisindione Uncurated Annotation Trazodone decreases the anticoagulant effect (source: Drug Bank)
aprepitant Uncurated Annotation The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed. (source: Drug Bank)
aripiprazole Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Aripiprazole by decreasing Ariprazole metabolism and clearance. Monitor for changes in Aripiprazole efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
atazanavir Uncurated Annotation The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed. (source: Drug Bank)
atomoxetine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Atomoxetine by decreasing Atomoxetine metabolism and clearance. Monitor for changes in Atomoxetine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
bosentan Uncurated Annotation The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed. (source: Drug Bank)
bromocriptine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
buspirone Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
cabergoline Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
caffeine Uncurated Annotation The CYP3A4 inhibitor, Caffeine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Caffeine is initiated, discontinued or dose changed. (source: Drug Bank)
captopril Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Captopril by decreasing Captopril metabolism and clearance. Monitor for changes in Captopril efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine Uncurated Annotation The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carvedilol Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Carvedilol by decreasing Carvedilol metabolism and clearance. Monitor for changes in Carvedilol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
chloroquine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Chloroquine by decreasing Chloroquine metabolism and clearance. Monitor for changes in Chloroquine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
chlorpromazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Chlorpromazine by decreasing Chlorpromazine metabolism and clearance. Monitor for changes in Chlorpromazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
cimetidine Uncurated Annotation The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed. (source: Drug Bank)
citalopram Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
clarithromycin Uncurated Annotation The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
clomipramine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Clomipramine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
clotrimazole Uncurated Annotation The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed. (source: Drug Bank)
conivaptan Uncurated Annotation The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed. (source: Drug Bank)
cyclosporine Uncurated Annotation The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed. (source: Drug Bank)
darunavir Uncurated Annotation The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed. (source: Drug Bank)
delavirdine Uncurated Annotation The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed. (source: Drug Bank)
desipramine Uncurated Annotation Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Desipramine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Desipramine by decreasing Desipramine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Trazodone and Desipramine efficacy/toxicity if either agent is initiated, discontinued or dose changed. (source: Drug Bank)
dexamethasone Uncurated Annotation The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed. (source: Drug Bank)
dextromethorphan Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Dextromethorphan by decreasing Dextromethorphan metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Dextromethorphan efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
dicumarol Uncurated Annotation Trazodone decreases the anticoagulant effect (source: Drug Bank)
dihydroergotamine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
diltiazem Uncurated Annotation The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed. (source: Drug Bank)
donepezil Uncurated Annotation Possible antagonism of action (source: Drug Bank)
doxepin Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Doxepin efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
doxorubicin Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Doxorubicin by decreasing Doxorubicin metabolism and clearance. Monitor for changes in Doxorubicin efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
doxycycline Uncurated Annotation The CYP3A4 inhibitor, Doxycycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Doxycycline is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Duloxetine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
efavirenz Uncurated Annotation The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed. (source: Drug Bank)
eletriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
ergonovine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
ergotamine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
erythromycin Uncurated Annotation The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed. (source: Drug Bank)
escitalopram Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
flecainide Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Flecainide by decreasing Flecainide metabolism and clearance. Monitor for changes in Flecainide efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
fluconazole Uncurated Annotation The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed. (source: Drug Bank)
fluoxetine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Fluoxetine by decreasing Fluoxetine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Fluoxetine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
fluphenazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Fluphenazine by decreasing Fluphenazine metabolism and clearance. Monitor for changes in Fluphenazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Fluvoxamine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
fosamprenavir Uncurated Annotation The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed. (source: Drug Bank)
fosphenytoin Uncurated Annotation The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed. (source: Drug Bank)
frovatriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
furazolidone Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
galantamine Uncurated Annotation Possible antagonism of action (source: Drug Bank)
ginkgo biloba Uncurated Annotation Increased effect and toxicity of both agents (source: Drug Bank)
haloperidol Uncurated Annotation The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed. (source: Drug Bank)
imatinib Uncurated Annotation The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed. (source: Drug Bank)
imipramine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Imipramine by decreasing Imipramine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Imipramine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
indinavir Uncurated Annotation The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed. (source: Drug Bank)
indinavir Uncurated Annotation This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
isocarboxazid Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
isoniazid Uncurated Annotation The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed. (source: Drug Bank)
itraconazole Uncurated Annotation The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed. (source: Drug Bank)
itraconazole Uncurated Annotation This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
ketoconazole Uncurated Annotation The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Uncurated Annotation This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
lapatinib Uncurated Annotation The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed. (source: Drug Bank)
lidocaine Uncurated Annotation The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The 2D6 inhibitor, Trazodone, may increase the efficacy of Lidocaine by decreasing Lidocaine metabolism and clearance. Monitor for changes in Trazodone and Lidocaine efficacy/toxicity if either agent is initiated, discontinued or dose changed. (source: Drug Bank)
linezolid Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
lithium Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
lomustine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Lomustine by decreasing Lomustine metabolism and clearance. Monitor for changes in Lomustine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
lopinavir Uncurated Annotation The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed. (source: Drug Bank)
maprotiline Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
meperidine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
methamphetamine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Methamphetamine by decreasing Methamphetamine metabolism and clearance. Monitor for changes in Methamphetamine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
methylergonovine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
metoprolol Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Metoprolol by decreasing Metoprolol metabolism and clearance. Monitor for changes in Metoprolol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
metronidazole Uncurated Annotation The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed. (source: Drug Bank)
mexiletine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Mexiletine by decreasing Mexiletine metabolism and clearance. Monitor for changes in Mexiletine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
miconazole Uncurated Annotation The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed. (source: Drug Bank)
mirtazapine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
moclobemide Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Moclobemide by decreasing Moclobemide metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Moclobemide efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
nafcillin Uncurated Annotation The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed. (source: Drug Bank)
naratriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
nebivolol Uncurated Annotation The CYP2D6 inhibitor, Trazodone, may increase the efficacy/toxicity of Nebivolol by decreaseing Nebivolol metabolism and clearance. Monitor for changes in blood pressure if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
nefazodone Uncurated Annotation Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Nefazodone by decreaseing Nefazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone and Nefazodone efficacy/toxicity if either agent is initiated, discontinued or dose changed. (source: Drug Bank)
nefazodone Uncurated Annotation This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
nelfinavir Uncurated Annotation The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed. (source: Drug Bank)
nevirapine Uncurated Annotation The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed. (source: Drug Bank)
nicardipine Uncurated Annotation The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed. (source: Drug Bank)
norfloxacin Uncurated Annotation The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed. (source: Drug Bank)
nortriptyline Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Nortriptyline by decreasing Nortriptyline metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Nortriptyline efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
oxcarbazepine Uncurated Annotation The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed. (source: Drug Bank)
paroxetine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Paroxetine by decreasing Paroxetine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Paroxetine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
pentobarbital Uncurated Annotation The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed. (source: Drug Bank)
pergolide Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
perphenazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Perphenazine by decreasing Perphenazine metabolism and clearance. Monitor for changes in Perphenazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
phenelzine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
phenobarbital Uncurated Annotation The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed. (source: Drug Bank)
phenytoin Uncurated Annotation The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed. (source: Drug Bank)
pipotiazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Pipotiazine by decreasing Pipotiazine metabolism and clearance. Monitor for changes in Pipotiazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
posaconazole Uncurated Annotation The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed. (source: Drug Bank)
primidone Uncurated Annotation The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed. (source: Drug Bank)
procainamide Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Procainamide by decreasing Procainamide metabolism and clearance. Monitor for changes in Procainamide efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
procarbazine Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
promethazine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Promethazine by decreasing Promethazine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Promethazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
propafenone Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Propafenone by decreasing Propafenone metabolism and clearance. Monitor for changes in Propafenone efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
protriptyline Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Protriptyline by decreasing Protriptyline metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Protriptyline efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
quinidine Uncurated Annotation The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed. (source: Drug Bank)
rasagiline Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
rifabutin Uncurated Annotation The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Uncurated Annotation The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifapentine Uncurated Annotation The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed. (source: Drug Bank)
risperidone Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Risperidone by decreasing Risperidone metabolism and clearance. Monitor for changes in Risperidone efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
ritonavir Uncurated Annotation Ritonavir increases levels/effect of trazodone (source: Drug Bank)
ritonavir Uncurated Annotation The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed. (source: Drug Bank)
rivastigmine Uncurated Annotation Possible antagonism of action (source: Drug Bank)
rizatriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
saquinavir Uncurated Annotation The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed. (source: Drug Bank)
selegiline Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
sertraline Uncurated Annotation Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Sertraline, may also increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The 2D6 inhibitor, Trazodone, may increase the efficacy of Sertraline by decreasing Sertraline metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Trazodone and Sertraline efficacy/toxicity if either agent is initiated, discontinued or dose changed. (source: Drug Bank)
sibutramine Uncurated Annotation Increased risk of serotonin syndrome. Avoid concomitant therapy. (source: Drug Bank)
sumatriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
tamoxifen Uncurated Annotation The CYP2D6 inhibitor, Trazodone, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy. (source: Drug Bank)
tamsulosin Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Tamsulosin by decreasing Tamsulosin metabolism and clearance. Monitor for changes in Tamsulosin efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
telithromycin Uncurated Annotation The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
tetrabenazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Tetrabenazine by decreasing Tetrabenazine metabolism and clearance. Monitor for changes in Tetrabenazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
tetracycline Uncurated Annotation The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed. (source: Drug Bank)
thioridazine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Thioridazine by decreasing Thioridazine metabolism and clearance. Monitor for changes in Thioridazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
timolol Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Timolol by decreasing Timolol metabolism and clearance. Monitor for changes in Timolol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
tipranavir Uncurated Annotation The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed. (source: Drug Bank)
tolterodine Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Tolterodine by decreasing Tolterodine metabolism and clearance. Monitor for changes in Tolterodine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
tramadol Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
trimipramine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Trimipramine by decreasing Trimipramine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Trimipramine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
venlafaxine Uncurated Annotation Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Venlafaxine by decreasing Venlafaxine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Venlafaxine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
verapamil Uncurated Annotation The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed. (source: Drug Bank)
voriconazole Uncurated Annotation The CYP3A4 inhibitor, Voriconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)
warfarin Uncurated Annotation Trazodone decreases the anticoagulant effect (source: Drug Bank)
zolmitriptan Uncurated Annotation Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
zuclopenthixol Uncurated Annotation The 2D6 inhibitor, Trazodone, may increase the efficacy of Zuclopenthixol by decreasing Zuclopenthixol metabolism and clearance. Monitor for changes in Zuclopenthixol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
Phenotype data available No genotype data Literature annotations available Not annotated
Depression
  •   
  •   
  • PK
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Long QT Syndrome
  •   
  • PD
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Torsades de Pointes
  •   
  • PD
  •   
  •   
  •   
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00656
KEGG Compound ID:
C07156
PubChem Compound ID:
5533
PubChem Substance ID:
172043
IUPHAR Ligand ID:
213

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.